In this video series, presented in April of 2020, GRACE Faculty and Members of the Board of Directors have a candid discussion regarding cancer and...
In this video series, presented in April of 2020, GRACE Faculty and Members of the Board of Directors have a candid discussion regarding cancer and...
In this video series, presented in April of 2020, GRACE Faculty and Members of the Board of Directors have a candid discussion regarding cancer and...
In this video series, presented in April of 2020, GRACE Faculty and Members of the Board of Directors have a candid discussion regarding cancer and...
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of...
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with...
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
The transition of PD1 and PD-L1 inhibitors into the first line setting for at least some patients with advanced non-small cell lung cancer (NSCLC) is...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.